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Introduction: Focal Ischemic Stroke
Acute ischemic stroke is one of the main causes of mortality 
and disability. It annually affects 93 new and recurrent cases 
per 100,000 population in the US, which imposes a direct eco-
nomic cost of over $73 billion.1 There is only one approved medi-
cal therapy for stroke: tPA is a “clot busting” agent that acts to 
reperfuse damaged brain, and must be given within 4.5 h of the 
stroke onset. However, the affected patients are left with life-
long motor, sensory and cognitive disabilities,2 which indicates 
that despite reperfusion associated with opening of an occluded 
blood vessel there exists non-salvaged and damaged brain tissues. 
Therefore neural repair strategies are required to improve neuro-
logical dysfunction.
The most common stroke subtype is non-hemorrhagic stroke, 
caused by a sudden arterial occlusion that disrupts blood flow 
to brain tissue3 and leads to tissue necrosis in the center of the 
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Focal stroke is a disabling disease with lifelong sensory, motor 
and cognitive impairments. Given the paucity of effective 
clinical treatments, basic scientists are developing novel 
options for protection of the affected brain and regeneration 
of lost tissue. Tissue bioengineering and stem/progenitor cell 
treatments have both been individually pursued for stroke 
neural repair therapies, with some benefit in tissue recovery. 
emerging directions in stroke neural repair approaches 
combine these two therapies to use biopolymers with stem/
progenitor transplants to promote greater cell survival in the 
transplant and directed delivery of bioactive molecules to the 
transplanted cells and the adjacent injured tissue. in this review 
the background literature on a combined use of neural stem/
progenitor cells encapsulated in hyaluronan gels is discussed 
and the way this therapeutic approach can affect the important 
processes involved in brain tissue reconstruction, such as 
angiogenesis, axon regeneration, neural differentiation and 
inflammation is clarified. The glycosaminoglycan hyaluronan 
can optimize those processes and be employed in a successful 
neural tissue engineering approach.
Hyaluronan, neural stem cells and tissue 
reconstruction after acute ischemic stroke
pouria Moshayedi and S. Thomas carmichael*
Department of Neurology; David Geffen School of Medicine at ucLa; Los angeles, ca uSa
Keywords: stroke, neural repair, regeneration, hyaluronan, brain
territory of occluded artery, known as the infarct core.3 Brain 
areas that are adjacent to the stroke and connected to the region 
that will become the infarct core survive the stroke. Evidence 
from human and animal studies indicates that plasticity in the 
regions of the brain adjacent to and connected with the stroke 
exhibit the most recovery of function.4-6 Mechanisms of recovery 
in these areas include neurogenesis, in which newly born imma-
ture neurons migrate into the peri-infarct cortex in large numbers 
and may provide a direct trophic support or cell replacement in 
this tissue. Also, axons in peri-infarct cortex sprout new connec-
tions by activating a specific “sprouting transcriptome.” Recovery 
is also seen in the remapping of motor and sensory maps in peri-
infarct cortex.4-6
However, this recovery is limited, making stroke the leading 
cause of adult disability. Neuronal circuits in peri-infarct cortex 
are stunned or dysfunctional, exhibiting increased inhibition7 
and altered responses to excitatory signals.8 Experimental studies 
have shown that the self-repair processes of axonal sprouting and 
neurogenesis could be enhanced by specific treatment directed 
at tissue reorganization, as opposed to neuroprotective strategies 
which maximize the extent of spared neurological functions by 
protecting the brain tissue against active cell death mechanisms.9 
Because neural repair processes occur over weeks and months 
after the stroke they may be amenable to more delayed treatments 
that could be given to a wider array of patients than acute neuro-
protective therapies.10
Ischemia, among many changes, induces the proliferation 
and migration of endogenous neural stem and progenitor cells 
(NSPCs) in the brain.5,11 These play a neuroprotective role by 
modulating intrinsic inflammatory responses to injury.12,13 
Transplanted stem/progenitor cells may enhance these endog-
enous processes after stroke such as axonal sprouting, neurogen-
esis and angiogenesis.13,14 Stem/progenitor cells can also directly 
integrate into damaged neural networks by differentiating into 
neurons and glial cells,15,16 although this does not appear to be a 
substantial element in the tissue repair after NSPC transplanta-
tion.17 Stem cell transplantation after stroke can both enhance 
endogenous repair processes and potentially create new neuronal 
circuits or brain architecture in partially damaged areas next to 
the stroke core. Therefore, stem cell transplantation is a therapeu-
tic option for post-stroke neural damage.
However, there are pre-clinical and clinical challenges that 
limit the application of neural stem/progenitor cells in stroke. 
Peri-infarct tissue is the area where the most significant post-stroke 
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Tissue engineering is a multi-faceted approach, as there are 
several pathologies in damaged tissues that should be corrected. 
The main deficit in stroke is due to the lost or damaged neuronal 
circuits. In order to repair injured circuits and possibly restore 
neurons glial support is needed, as well as a vasculature to supply 
oxygen and nutrients. Inflammation with both its destructive and 
constructive roles actively contributes to the brain tissue response 
to the implanted hydrogel. An efficacious hydrogel design, there-
fore, should take these into consideration and analyze interac-
tions of the hydrogel elements with the injured brain tissue. We 
explore in this review the interactions of HA with the processes 
involved in inflammation, foreign body response, angiogenesis, 
NPC differentiation and axon growth.
Hyaluronan
HA is a glycosaminoglycan composed of repeated disacharid 
D-glucuronic acid and N-acetyl-D-glucosamine. It is produced 
by a membrane-bound group of enzymes named hyaluronan 
synthases, which organize D-glucuronic acid and N-acetyl-D-
glucosamine disacharids into a non-branched linear polymer 
that can range between 1 MDa to 4 MDa in size; this is what 
generally known as high molecular weight (HMW) HA. HMW 
HA is very flexible and can readily form into coils, nets or fibers22 
(see an electron micrograph in Fig. 1). HMW HA is strongly 
negatively charged and therefore absorbs up to 10–10,000 times 
its weight water.23 It is generally a bio-inert molecule that acts to 
maintain a hydrated and porous environment, absorbs mechani-
cal shock and regulates osmotic balance. HMW HA can also 
sequester and gradually release growth factors and other bio-
active molecules to communicate a local biological influence 
over cells. HMW HA is specifically interesting from a tissue 
Table 1. application of biopolymers in neural stem/progenitor cell therapy of focal brain ischemic lesion
Article
Stroke 
model/
species
Cells transplanted/den-
sity per animal
Hydrogel Outcomes
Bible et al., 200972 Mcao/rat
NSc/ 
3.15 × 105 cells in 30 µl
Fibronectin-coated 
pLGa particles
Descriptive analyses of cell survival, cell-scaffold-tissue 
integration, cell differentiation, angiogenesis and host 
inflammatory response
Jin et al., 201073 Mcao/rat
heS-Npc/ 
6 × 106 cells in 50 µl
Matrigel
Reduction in lesion volume, improving cell survival, dif-
ferentiation and behavioral indices
Yu et al., 201074 Mcao/rat
NSc/ 
1.5 × 104 in 5 µl
collagen
cell survival, NSc synapse formation and neurological 
severity score improved
Zhong et al., 201014 pT/mice
eS-Npc / 
105 cells in 7 µl
Hyaluronan 
/Heparin 
/collagen
improving transplant cell survival and host inflamma-
tory response, angiogenesis and astrocytic reactivity
Matsuse et al., 201175 Mcao/rat
MS-NSc/ 
2 × 104 cells, 12 µl in stri-
atum and 8 µl in cortex
collagen with 
bFGF in gelatin 
microspheres
infarct volume, cell survival and distribution, angio-
genesis, number of host NScs and motor behavior 
improved
Bible et al., 201276 Mcao/rat
hNSc 
/2.1–2.5 × 106 cells in 
25–40 µl
acellular ecM
Descriptive analyses of cell imaging by MRi, cell migra-
tion, differentiation and cell-host tissue interaction
eS, embryonic stem; h, human; Mcao, middle cerebral artery occlusion; MS, mesenchymal stem; Npc, neural precursor cell; NSc, neural stem cell; 
pLGa, poly(lactic-co-glycolic acid); pT, photothrombotic.
regeneration occurs5 and therefore transplanted cells need to be 
delivered as close as possible to that area for a maximum effect 
on the recovering circuits after stroke. However, direct injection 
of stem/progenitor cells into the peri-infarct cortex carries the 
theoretical risk of damaging the very tissue that recovers after 
stroke.18 The infarct cavity is a compartmentalized area of dead, 
loose tissue that provides a potential space for cell transplantation 
and it is located adjacent to the peri-infarct zone.19 However, cells 
injected into this cavity encounter inflammation, lack of blood 
supply and pro-apoptotic factors and subsequently die.20 The 
necrotic core of infarcted tissue does not provide transplanted 
cells with a viable matrix and required growth factors to help 
them regenerate and reorganize the damaged tissue. As infarcted 
or damaged tissue is a target for neural repair in stroke and other 
CNS degenerative diseases the limited vascular and trophic sup-
port and increased inflammation in this target region can be an 
explanation as to why clinical stem cell therapy had limited suc-
cess or variable outcome in patients suffering from disorders such 
as stroke and Parkinson.21
A potential solution to stem cell targeting in stroke is the 
encapsulation of neural stem/precursor cells in a bio-compatible 
matrix to enhance their survival and/or differentiation in stroke. 
Such a matrix might provide signals through the structure of the 
hydrogel backbone, the incorporation of growth factors or the 
inclusion of protein motifs that provide pro-survival, pro-growth 
or pro-differentiation effects. There have been several studies 
applying biopolymers as carrying scaffolds for neural stem/pro-
genitor cells transplanted to brain focal ischemic lesions (Table 
1). In this review, we will focus on the use of Hyaluronan (HA) 
and discuss options for a bio-compatible hydrogel matrix with a 
potential to enhance the outcomes of neural cell transplantation 
for brain ischemic lesions.
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accessing normal brain tissue and will effectively cause implant 
malfunction. From the anti-inflammatory effects of HMW HA 
it might be predicted that HA will reduce scar formation in the 
brain and peripheral nerves. This is indeed true:39,40 Figure 2 
shows how applying HMW HA can attenuate astrocytic reactiv-
ity and scar formation in spinal cord injury. These data render 
HA gel a bio-compatible choice for neural tissue engineering.
Hyaluronan and Angiogenesis
Nutrients and oxygen can functionally diffuse up to 150–250 μm 
from blood capillaries.25 The size of infarcted tissue in the brain 
is several fold larger than this critical range. Therefore any tissue 
engineering solution for the brain after stroke should consider 
reconstructing a normal microenvironment with a proper accessi-
bility to oxygen and nutrients, and envisage a solution for the for-
mation of new vessels in tissue constructs. Angiogenesis requires 
activation of endothelial cells with pro-angiogenic factors (such 
as vascular endothelial growth factor or VEGF, platelet-derived 
growth factor or PDGF, fibroblast growth factor or FGF, hepatic 
engineering standpoint as it can diminish the interaction of 
encapsulated cells with other cells and growth factors and there-
fore “conceal” them from local harmful signals; this is mainly 
done by modulating inflammatory response of macrophages.24 
HMW HA can be degraded by enzymes, hyaluronidases, into 
oligomers that, unlike high molecular HA, are highly bioac-
tive (see below). HA degradation is facilitated in inflammation 
and injury by the production of reactive oxygen and nitrogen 
species.25
HA is a reasonable choice to encapsulate cells for transplan-
tation into the brain because it is naturally and abundantly 
found in the brain.26 HA has a role in the brain more than just 
space-filling, hydration and matrix provision. HA influences cell 
adhesion, migration, axon path-finding, brain regional specific-
ity and therefore, it is actively involved in normal development 
of the brain.26,27 HA is increasingly deposited in the aged brain 
and diminishes oligodendrocyte precursor (OPC) maturation.28 
HA in the demyelinated plaques of multiple sclerosis prohibits 
OPC maturation and myelin repair.31 HA is a component of the 
perineuronal net that modulates mature cerebral neurons.29 HA 
is also involved in brain pathologies and diseases. HA promotes 
malignant glial cell adhesion, migration and metastasis in the 
brain.28 It also contributes to mossy fiber sprouting in the hip-
pocampus that will eventually lead to temporal lobe epilepsy.27 
HA is involved in immunomodulation, tissue injury and repair 
in the brain through the innate immune receptors toll-like recep-
tors 2 and 4 (TLR2 and TLR4), signaling through the main 
inflammatory transcription factor NFκB, and tumor necrosis 
factor α secretion.26,30 These phenomena are mediated through 
HA receptors, mainly CD44, RHAMM and TLR4. Hence, HA 
affects a variety of physiologic and pathologic functions, which 
makes its application intriguing and challenging.
HA gives different biological signals depending on the molec-
ular weight (see Table 2 for an overview). High molecular HA 
(> 500 kDa) that is normally found in the brain plays a structural 
role and silences inflammation, angiogenesis and neural differ-
entiation.32-34 But in pathologies, such as brain ischemic stroke, 
HA is fragmented into 6- to 40-mers through the action of hyal-
uronidases and reactive oxygen or nitrogen species. Fragmented 
HA has a distinct role in activating innate and adaptive immune 
response, as well as inducing proliferation, motility, and tubule 
formation of endothelial cells and angiogenesis (refs. 35 and 36 
and personal communication with M. Slevin). This effect is 
mediated by HA receptor CD44 on the endothelial cells.37 This 
allows tissue engineers to vary the molecular sizes of HA. By 
encapsulating cells in high molecular weight HA, cells can be 
transplanted and protected from inflammation upon transplanta-
tion in the acute phase of brain damage and through a controlled 
and gradual degradation, low molecular weight HA is released 
and can induce angiogenesis and differentiation of stem cell.
Every material implanted in the brain is at risk of being iso-
lated by the brain foreign body response.38 This starts with the 
brain’s attempt to heal the wound caused by implantation. Upon 
failure to recognize the implant as “self” or to degrade it, the brain 
mounts a chronic activation of inflammatory response and gliotic 
scar formation that will eventually seal-off the “stranger” from 
Figure 1. Scanning electron micrograph of Ha hydrogel at (A) lower or 
(B) higher magnification. Reproduced with permission from reference 
77. Scale bar = (A) 50 μm and (B) 20 μm.
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also enhances matrix metallopro-
teinase (MMP)-2 and -9 expression, 
promoting matrix degradation and 
progression of angiogenesis. MMPs 
also activate endogenous TGF-β that 
in turn contributes to angiogenesis. 
Interactions of short chain HA with 
RHAMM lead to cytoskeletal changes 
and subsequent migration of endothe-
lial cells that further contribute to the 
formation of new vessels.26
Growing human umbilical vein 
endothelial cells (HUVECs) on HA 
gels improved their proliferation. 
This augmentation was proportional 
to the concentration of HA and by 
using 1% HA gel cells maximally 
increased their proliferation over 
2-fold in a 48 h interval. HA also 
protects HUVECs against apoptosis 
induced by serum deprivation. An HA 
gel enhanced angiogenesis, arterio-
gensis and improved ischemia in an experimental model of mice 
limb ischemia when it encapsulated HUVECs.43 Implanting HA 
hydrogels in the brain has improved angiogenesis.44 HA is also 
important in maintaining vascular integrity.45 These data show 
HA has the potential to support the formation of a vasculature 
to allow generation and survival of engineered constructs in sizes 
required to replace the infarcted brain tissue. Some studies have 
bound oligomeric HA to culture surfaces and thereby induced 
endothelial cell proliferation and tube formation.46 An alternative 
approach would be to engineer HMW HA gels to persistently 
degrade and provide host tissue endothelial cells with a continu-
ous source of pro-angiogenic oligomeric HA.47
Interaction of endothelial cells with a plain or unmodified HA 
gel is often not sufficient to make a patent vasculature. Chemical 
engineering can help to further enhance angiogenesis in HA gels 
by introducing components of extracellular matrix (ECM) mol-
ecules such as fibronectin48 or fibronectin-derived synthetic pro-
tein motifs.44 Other studies have shown HA gels that gradually 
release pro-angiogenic growth factors VEGF or bFGF have an 
improved angiogenesis.26
growth factor or HGF, angiopoietin-1 and transforming growth 
factor-β or TGF-β). These factors induce a process of endothe-
lial branching from existing capillaries into adjacent tissue and 
penetration into an implanted matrix. Endothelial cells need to 
survive and proliferate inside such a transplanted matrix, and be 
capable of remodeling it to migrate through and establish pre-
liminary cord-like capillary structures; these will advance into 
mature capillaries and further to small arteries and veins.
HA has been widely studied and appreciated as a pro-
angiogenic tool in tissue engineering because it can initiate and 
maintain angiogenesis. HMW HA promotes quiescence in endo-
thelial cells, but oligomeric HA promotes their proliferation and 
migration; this effect is mediated directly through endothelial 
cells and also indirectly by inducing inflammatory cells to secrete 
pro-angiogenic factors. HA relays these messages through CD44, 
RHAMM and TLR-4 receptors.26,41,42 Long polymers of HA 
bind to CD44 and interfere with any biological signal transduc-
tion; this inhibits endothelial cell proliferation that leads to arrest 
of angiogenesis. Oligomeric HA, in contrast, attaches to CD44 
and promote proliferation of endothelial cells. This molecule 
Table 2. a comparative summary of findings in high molecular weight Ha vs. low molecular weight Ha
High molecular weight hyaluronan Low molecular weight hyaluronan
- provides hydration and porosity
- Sequesters and gradually releases bioactive molecules
- conceals encapsulated cells from other cells and humoral factors
- Keeps stem/progenitor cells in a quiescence state
- Silences inflammation
- prohibits angiogenesis
- inhibits astrocyte activation and scar formation
- activates immune response
- induces angiogenesis
- promotes proliferation, differentiation and migration  
of stem/progenitor cells
Figure 2. attenuation of astrocyte activation and deposition of chondroitin sulfate proteoglycan 
(cSpG) by HMw Ha gel injection in vivo. Longitudinal images of spinal cord from control (“Sci”) and 
Ha-implanted animals are shown 10 d after spinal cord injury (Sci). Reproduced with permission from 
reference 39. Scale bar = 100 μm.
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HA content in the postnatal period.14 It is therefore possible to 
utilize the dual effect of HA on stem cells by encapsulation of 
NSPCs in high molecular size HA to prohibit proliferation and 
maturation, and by a timely degradation of HA and provision of 
cells with LMW HA turn on their proliferation and differentia-
tion machinery.
These data have inspired researchers to employ HA hydrogel 
to recapitulate the normal stem cell niche: by providing NSPCs 
with a 3-dimensional matrix close in composition to the ECM, 
and by further supplementing HA hydrogel with collage-I, abun-
dantly found in basal lamina of the subventricular zone.56 Cells 
growing in these gels have a lower proliferation rate compared 
with a 2-dimensional culture, and their neural differentiation 
improves by almost 5-fold. Other research groups have enriched 
HA gels with an optimized ratio of collagen57 or added carefully-
tuned amounts of fibroin (produced by Bombyx mori silkworm50), 
heparin sulfate14 or IKVAV (a protein motif originally found in 
laminin) plus brain-derived neurotrophic factor58 to provide 
NSPCs with an optimally engineered microenvironment to 
improve their survival, proliferation and differentiation. By alter-
ing the hydrogel compliance instead of changing biochemical 
factors, differentiation of NSPCs to neurons was optimized in 
gels mimicking neonatal brain compliance vs. those gels simi-
lar to adult brain in elasticity.59 Neural progenitor cells (NPCs) 
encapsulated in a combined hydrogel made of HA, heparin sul-
fate and collagen transplanted to the stroke cavity were protected 
against the host inflammatory insult and their survival improved 
(Fig. 4).14 Applying this biopolymer matrix, however, did not 
influence NPCs differentiation.
Hyaluronan and Axon Growth
Attempts to study the role of HA in axonal local sprouting and 
long-distance regeneration started with simple histological obser-
vations in late 1980s.60 These found HA as a fine mesh around 
brain and spinal cord myelinated axons,61,62 as well as in endo-
neurial tubes in the peripheral nerves.63 HA was also found in the 
perineuronal nets, the specialized ECM structures around cell 
bodies in the CNS that among many roles also regulate synaptic 
connectivity.61,62
These phenomenological studies had a clear conclusion: HA 
is likely to affect a neuron’s physiological functions in the devel-
oping and adult nervous system, and also could determine the 
regenerative response to nervous system injuries. These were the 
foci for further investigations. HA was found to fine-tune axon 
pathfinding and contribute to architecturally specific areas in 
the brain: layer-specific termination of entorhinal fibers to the 
dentate gyrus, an area responsible for formation of new memo-
ries, was abolished by degrading HA molecules.64 Another region 
that HA serves as a guidance molecule is the optic chiasm, where 
those axons of the optic nerve coming from the nasal halves of 
retina will cross and give rise to the very specific optic pathway. 
HA localizes in the medial part of the optic chiasm, the point 
where axon crossing takes place.65 Data suggests the HA recep-
tor CD44 is involved in mediating the HA role in axon crossing. 
Hyaluronan and Neural Stem/Progenitor Cells
There are many indications that HA influences neural stem/pro-
genitor cells in neural tissue development and therefore HA is a 
suitable candidate to encapsulate NSPCs in neural tissue engi-
neering. HA content is high in developing brain and it declines to 
25% two weeks after birth.49 In vitro studies show that the addi-
tion of HA contributes to increasing water absorption and poros-
ity of bio-matrices.50 Water absorption and resultant changes in 
the three dimensional HA structure are responsible for some of 
its biological properties. For example, HA is associated with neu-
ral crest cell distribution along the neural tube perhaps by creat-
ing a porous milieu for cell migration through the tight cell-cell 
junction of neuroepithelial cells. Ninety percent of HA is associ-
ated with water, suggesting HA contributes to cell migration by 
providing a loose matrix. HA is diffusely found in the developing 
brain while NSPCs are migrating in radial or tangential direc-
tions. Although HA decreases in postnatal brain, it is still found 
in cerebellum and corpus callosum, where HA is re-organized 
into dense meshworks; interestingly, those areas are home to an 
extensive migration of progenitor cells.26
Besides being a permissive conduit for migration, HA actively 
interacts with cells to tune the cellular machinery for migration. 
Through RHAMM receptors HA induces calmodulin-mediated 
signaling that affects actin and microtubule.51 HA-rich fiber 
tracts may also function as physical cues guiding the migration 
of newly born cells in the CNS.26 It has been suggested that HA 
induces neural progenitor migration through RHAMM activa-
tion. CD44, another known receptor for the HA molecule, is 
found on NPCs and mediates their interaction with endothelial 
cells and their transmigration through vessels;52 these stem cell 
functions lead to establishing neurovascular stem cell niche that 
plays a crucial role in normal adult angiogenesis as well as inte-
gration of exogenous transplanted NSPCs.
HA is found in the niche surrounding stem cells and it affects 
stem cell proliferation and differentiation. It is specifically found 
in the brain ventricular regions with ongoing stem cell prolifera-
tion.26 HA interaction with CD44 receptor on stem cells influ-
ences mitosis spindle formation, which in turn affects symmetric 
vs. asymmetric division and therefore controls self-renewal vs. 
differentiation.53 HA is generally believed to slow the prolifera-
tion of stem cells in the brain. Enzymatic HA removal induces 
proliferation of oligodendrocyte-type 2 astrocyte progenitors,54 
now classified as oligodendrocyte progenitor cells. HA is partly 
the reason for failed remyelination of demyelinated axons in 
multiple sclerosis by oligodendrocyte progenitor cells (see 
Fig. 3 for an illustration): While HMW HA secreted by astro-
cytes in demyelinated lesions prohibits OPC differentiation to 
myelin-producing cells, removing HMW HA promotes oligo-
dendrocyte maturation.31 On the other hand, it has been sug-
gested that degradation of HA promotes proliferation of cells.55 
Moreover, LMW HA (as the degradation product of HMW 
HA) can induce proliferation, differentiation and migration of 
NSPCs.26 Degradation of HA gels encapsulating neural progeni-
tor cells causes differentiation and maturation of those cells; this 
fits well with the in vivo finding showing a decline in the brain 
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is responsible for the formation of a recurrent aberrant excitatory 
network and the consequent temporal lobe epilepsy. Increases in 
HA expression in the hippocampus are associated with temporal 
lobe epilepsy and removing HA in the dentate gyrus protects the 
brain from epileptogenic chemicals (e.g., kainic acid) that induce 
mossy fiber sprouting.27
These findings prompted researchers to apply HA to promote 
regeneration in the peripheral and the central nervous systems. 
Their initial concept considered HA as a hydrated open lattice 
to allow axon growth as well as free diffusion of nutrients and 
Further experiments revealed HA removal deters axon crossing 
in the optic chiasm.66
HA is also involved in the nervous system response to inju-
ries and pathological conditions. The presence of HA was cor-
related with the axon growth in regenerating limbs of larval 
ambystoma.60 This finding was echoed in a murine model of 
peripheral nerve injury: HA was associated with successful axon 
regeneration and it was co-localized in Schwann cells prolifera-
tion areas and the bands of Büngner, two heralds of endogenous 
peripheral nerve repair.63 Mossy fiber sprouting in hippocampus 
Figure 3. an illustrative model on how changes in Ha regulate NSpcs in normal state and in response to injury. (1) cNS insults activate NSpcs in the 
subventricular zone (SvZ); (2) Ha in the niche is degraded due to increased hyaluronidase activity of NSpcs and other cell types and therefore (3) 
NSpcs proliferate, migrate toward the lesion and differentiate to opcs. (4) However, their maturation is inhibited if they encounter HMw Ha-rich 
chronic lesions. Reproduced with permission from reference 26.
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there exists a dual functional role of HA by size (see Table 2) 
and therefore a successful tissue engineering approach requires 
an intelligent construction, maintenance and degradation of the 
HA hydrogel.
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growth factors. Early attempts applied an injectable form of HA 
to amplify axon growth, myelination and conduction velocity in 
regenerating peripheral nerve.67,68 HA also diminished the peri-
neural scar formation, a known impediment to the regeneration, 
in re-opposed stamps of peripheral nerves.40
HA promoted regeneration of dorsal root ganglia axons in 
vitro, but it failed in vivo to induce spinal cord regeneration.69 
These findings revisit the established concept of compromised 
axon regeneration in the CNS. CNS axons are facing multiple 
barriers in their internal machinery as well as their surrounding 
environment in order to mount an effective regenerative response 
and therefore additional molecules are required to persuade sev-
ered axons to re-grow. Hence plain HA gels were supplemented 
with elements of the ECM or membrane receptor ligands to pro-
mote axon growth into the implanted HA matrix in the lesioned 
brain70 or spinal cord.71
Perspectives and Caveats
Tissue engineering will fail if it does not address the many 
pathologies present in the damaged brain tissue. In early stages of 
neural repair a focus was on neuronal replacement. However, con-
trolling inflammation, securely delivering stem/progenitor cells, 
promoting angiogenesis, inducing axon regeneration and evading 
the foreign body reaction are examples of demands from the local 
environment in a more biologically active tissue repair approach. 
Further, these are not distinct processes but are inter-related. As 
discussed in this review, HA is present in the developing and 
adult brain with a functional consequence for interaction with 
angiogenesis, inflammation, axonal and cell migration guidance 
and with effects on cell proliferation and differentiation. This 
implies applying HA in tissue constructs will modulate inflam-
mation, angiogenesis, stem cell proliferation/differentiation and 
axon regeneration and therefore improve brain ischemic lesions. 
In addition to those, tissue engineering capabilities of HA for 
protein motif incorporation indicate a future in which HA can 
serve to influence not just the individual elements of tissue repair, 
but multiple aspects of tissue repair at the same time. However 
Figure 4. Hyaluronan–heparin–collagen hydrogel improves the 
survival of neural progenitor cells (Npcs) transplanted into the infarct 
cavity after stroke. Npcs derived from the embryonic cortex were trans-
planted into the infarct cavity 7 d after stroke, with or without hydrogel; 
14 d after transplantation, transplanted cells were identified by the 
immunostaining of green fluorescent protein (GFp); the infarct cavity 
was identified by counterstaining with Dapi (4',6-diamidino- 2-phenyl-
indole). Reproduced with permission from reference 14.
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